Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (284)	2/16/1999 11:39:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 804

its side effect profile was comparable to its racemate Miljenko/Peter/SEPR freaks........ I don't understand.... if the side effect profile is no different from racemate, will FDA insist on substitution in any event? Why test a product where there is no clinical benefit? I'm pleased to see the progress, but.... I'm confused.... where do they go from here? Yes, I saw this...... The study had also suggested that Celgene's chirally pure formulation might possess a longer- lasting therapeutic benefit than equivalent dosage amounts of the racemic version. Boy, this release really threw me off..... I must have missed some important stuff...... why is it necessary to run separate trials in Canada? When did the pivotal trial start in the U.S.? I've been focused on T/MM and the SelCIDs. Please help! :-) Thanks!